DARBID
LOE ApproachingNDAORALTABLET
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARBID is an oral small-molecule tablet approved by GSK in 1957 with an unknown mechanism of action and indication profile. The drug's specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
As LOE approaches, the brand team will likely consolidate and shift focus toward lifecycle extension or managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero actively linked jobs and an LOE-approaching lifecycle indicate this is not a growth career opportunity; roles are primarily defensive and focused on maximizing residual value during the transition to generic competition. Professionals on this team are typically managing portfolio wind-down or preparing for role reassignment.
Brand ManagerCommercial Operations
Worked on DARBID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.